Generali Asset Management SPA SGR Has $5.93 Million Holdings in IQVIA Holdings Inc. $IQV

Generali Asset Management SPA SGR grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 37,624 shares of the medical research company’s stock after buying an additional 8,689 shares during the quarter. Generali Asset Management SPA SGR’s holdings in IQVIA were worth $5,929,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after buying an additional 312,807 shares during the period. JPMorgan Chase & Co. boosted its position in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the last quarter. American Century Companies Inc. boosted its position in IQVIA by 26.8% during the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after acquiring an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after acquiring an additional 854,732 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IQV. Truist Financial increased their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. HSBC raised IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Trading Down 0.7%

Shares of NYSE:IQV opened at $203.38 on Thursday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.21. The company has a market capitalization of $34.58 billion, a P/E ratio of 29.43, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32. The company has a 50-day simple moving average of $190.38 and a 200 day simple moving average of $168.79. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period last year, the firm posted $2.64 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.